Trial Profile
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1467335 in Healthy Japanese Male Volunteers With Multiple Oral Doses at the Highest Dose in Caucasian for Comparison (Randomised, Double-blind, Placebo-controlled Trial)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Jun 2021
Price :
$35
*
At a glance
- Drugs BI 1467335 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 03 Jan 2018 Status changed from active, no longer recruiting to completed.
- 07 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 13 Jun 2017 Status changed from not yet recruiting to recruiting.